Omega-3 apparently beneficial in heart failure, but rosuvastatin fails


Two studies based on the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico – Heart Failure) trial showed that statin treatment with rosuvastatin (AstraZeneca’s Crestor) had no effect in patients with chronic heart failure, while a simple, one-a-day capsule of omega-3 polyunsaturated fatty acids (PUFA) can reduce mortality and admission to hospital for cardiovascular reasons in patients with heart failure. The two studies, presented at the European Society of Cardiology (ESC) congress in Munich, Germany, were published online in the Lancet in August.